

Carfilzomib (Doublet Therapy) - In Combination with Dexamethasone for Relapsed Multiple Myeloma

(This form must be completed before the first dose is dispensed.)

1. Patient Profile

* Surname:

* Given Name:

* OHIN: * Chart Number:

* Postal Code:

* Height (cm): * Weight (kg):

* BSA (m²): * Gender: Male Female Other

* Date of Birth:
Day Month Year

* Site:

* Attending Physician (MRP- Most Responsible Physician):

Requested Prior Approval Yes * Patient on Clinical Trial Yes No

Other (specify):

Specify Arm:
 Standard of care arm Experimental arm
 Blinded / Unknown

Request prior approval for enrolment

* Justification for Funding

Anticipated date of first treatment
Day Month Year

2. Eligibility Criteria

The patient must meet the following criteria:

- Carfilzomib is used in combination with dexamethasone for patients with relapsed myeloma with a good performance status who have received one to three prior treatments. Yes

3. Baseline Information

- a. ECOG Performance Status at the time of enrolment 0 1
 2
- b. Number of prior treatments: 1 2
 3
- c. Is the patient transitioning from a private payer or compassionate program? Yes No
- d. If yes, please indicate the number of milligrams the patient received prior to transitioning to NDFP funding:

4. Funded Dose

Cycle 1 - carfilzomib 20 mg/m² days 1 and 2, followed by carfilzomib 56 mg/m² days 8, 9, 15, 16

Cycle 2 and beyond - carfilzomib 56 mg/m² days 1, 2, 8, 9, 15, 16

Carfilzomib is funded when used in combination with dexamethasone (ST-QBP regimen code: CARFDEXA).

5. Notes

1. Retreatment with carfilzomib is not publicly funded (i.e. if patients previously received carfilzomib, regardless of funding source, they are not eligible to receive carfilzomib under this policy).
2. Carfilzomib must be initiated with dexamethasone to be eligible for funding.

6. FAQs

i. My patient is currently receiving carfilzomib through Amgen's Victory program. Can my patient be transitioned over to receive funding through the New Drug Funding Program (NDFP)?

Patients who enrolled in the Victory program prior to May 1, 2018 and are currently receiving treatment through the program will continue to receive treatments through Victory until June 8, 2018. After this date, patients who met public funding criteria at the point of treatment initiation may transition to NDFP funding for the remainder of their treatment course.

ii. My patient completed 18 cycles of carfilzomib as part of triplet therapy with good response, but is now showing signs of relapse. Can I now treat with carfilzomib and dexamethasone?

CCO will fund one course of treatment with carfilzomib for each patient with relapsed myeloma, either as part of a doublet or triplet, for carfilzomib-naïve patients. If a patient completes 18 cycles of carfilzomib as part of triplet therapy, regardless of funding source, they will not be eligible for further treatments with carfilzomib at the point of relapse.

iii. My patient has been treated with an alternate regimen for relapsed multiple myeloma. How can my patient access carfilzomib?

Please refer to the attached funding algorithm for funded treatments for relapsed multiple myeloma. If the patient meets criteria for both carfilzomib and lenalidomide, CCO will fund carfilzomib as part of triplet therapy for relapsed myeloma. Patients who are refractory to bortezomib and/or lenalidomide may be funded for carfilzomib in combination with dexamethasone as a doublet therapy.

7. Supporting Documents

If the patient does not have previous bortezomib treatments in eClaims, please upload clinic notes indicating the previous treatment history.

In the event of an audit, the following should be available to document eligibility:

- Clinic notes indicating treatment history.

Signature of Attending Physician (MRP-Most Responsible Physician):

.....
Day Month Year